Codexis Daily News Today

Codexis (NASDAQ:CDXS – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at Benchmark in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $9.00 target price on the biotechnology company’s stock. Benchmark’s target price suggests a potential upside of 129.59% from the stock’s current […]

Codexis, Inc. (NASDAQ:CDXS – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the six analysts that are covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month price target among analysts that have […]

Codexis, Inc. (NASDAQ:CDXS – Get Free Report) has earned an average rating of “Moderate Buy” from the six research firms that are covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price target among […]

Codexis, Inc. (NASDAQ:CDXS – Get Free Report) has received an average rating of “Moderate Buy” from the six analysts that are covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among […]

Paradigm Capital Management Inc. NY grew its holdings in Codexis, Inc. (NASDAQ:CDXS – Free Report) by 66.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 500,000 shares of the biotechnology company’s stock after buying an additional 200,000 shares during the quarter. Paradigm […]

Shares of Codexis, Inc. (NASDAQ:CDXS – Get Free Report) have earned a consensus rating of “Moderate Buy” from the six brokerages that are covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1 year […]

Shares of Codexis, Inc. (NASDAQ:CDXS – Get Free Report) have received an average recommendation of “Moderate Buy” from the six analysts that are presently covering the stock, MarketBeat reports. Three research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12-month price objective […]

StockNews.com upgraded shares of Codexis (NASDAQ:CDXS – Free Report) to a sell rating in a research report released on Wednesday. Other analysts also recently issued research reports about the company. Piper Sandler reduced their price objective on Codexis from $14.00 to $10.00 and set an overweight rating for the company in a research report on […]

Trellus Management Company LLC decreased its position in shares of Codexis, Inc. (NASDAQ:CDXS – Free Report) by 12.5% during the third quarter, HoldingsChannel reports. The firm owned 220,000 shares of the biotechnology company’s stock after selling 31,460 shares during the period. Trellus Management Company LLC’s holdings in Codexis were worth $416,000 at the end of […]

Stock analysts at Cantor Fitzgerald assumed coverage on shares of Codexis (NASDAQ:CDXS – Get Free Report) in a report issued on Thursday, Marketbeat Ratings reports. The brokerage set an “overweight” rating and a $11.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 225.44% from the stock’s […]